ClinicalTrials.gg
TerminatedNCT06721156Updated Jul 1, 2026

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

A Phase 2 interventional study of MK-1167 and Placebo in Alzheimer Disease and Dementia, sponsored by Merck Sharp & Dohme LLC. Terminated at 72 sites in 9 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Termination Notes: Business reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Alzheimer Disease by Merck & Co., Inc — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Merck & Co., Inc.

Enrollment
4th of 29
369 · median 34
Started
2024
with 2 others
Phase 2
8 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Alzheimer Disease by Merck & Co., Inc, this one is the 4th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2024, is one of 8 in phase 2, and was the 30th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 31 studies in Alzheimer Disease by Merck & Co., Inc is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Alzheimer Disease by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.

The goals of this study are to learn:

  • If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
  • About the safety of MK-1167 and if people tolerate it
03

Conditions studied

  • Alzheimer Disease
  • Dementia
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has mild to moderate Alzheimer's Disease (AD) dementia (ie, Stage 4 or Stage 5 AD) based on the Alzheimer's Association Revised Criteria for Diagnosis and Staging of Alzheimer's Disease
  • Has a (MMSE) score of 12 to 24 (inclusive)
  • Is using acetylcholinesterase inhibitors (AChEI) therapy for management of AD dementia
  • Has a designated study partner who can fulfill the requirements of this study. The study partner will need to spend sufficient time with the participant to be familiar with their overall function and behavior and be able to provide adequate information about the participant needed for the study including, knowledge of functional and basic activities of daily life, work/educational history, cognitive performance, emotional/psychological state, and general health status

Exclusion criteria

Exclusion Criteria:

  • Has a known history of stroke or cerebrovascular disease
  • Has diagnosis of a central nervous system (CNS) disease other than AD dementia or other condition that negatively impacts cognition or cognitive status chronically
  • Has structural brain disease
  • Has a history of seizures or epilepsy
  • Has any other major CNS trauma, or infections that affect brain function (eg, (HIV), syphilis, and/or neurological sequelae of Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (COVID-19), including impact on cognition)
  • Has major medical illness or unstable medical condition
  • Has a history of
  • Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision (with protocol-specified exceptions)
  • Has liver disease, including but not limited to chronic viral hepatitis, nonviral hepatitis, cirrhosis, malignancies, liver diseases
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    MK-1167 3 mg

    Participants receive 3 mg of MK-1167 once daily (QD) for up to approximately 24 weeks.

    Drug: MK-1167

  • Experimental
    MK-1167 1 mg

    Participants receive 1 mg of MK-1167 QD for up to approximately 24 weeks.

    Drug: MK-1167

  • Experimental
    MK-1167 0.3 mg

    Participants take 0.3 mg of MK-1167 QD for up to approximately 24 weeks.

    Drug: MK-1167

  • Placebo comparator
    Placebo

    Participants take placebo QD for up to approximately 24 weeks.

    Drug: Placebo

Interventions

  • MK-1167 oral capsule

  • DrugPlacebo

    Placebo oral capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11) Total Score at Week 24

    The change from baseline in ADAS-Cog11 score at Week 24 is presented. ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The total possible score ranges from 0 to 70, with higher scores indicating greater cognitive impairment. Negative values indicate improvement relative to baseline, and vice versa.

    Time frame: Baseline and up to approximately 24 weeks

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 28 weeks

  3. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 24 weeks

Secondary outcomes

  1. Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall Score at Week 24

    The overall score in ADCS-CGIC at Week 24 is presented. The ADCS-CGIC is a clinician-rated measure of change in global severity from baseline, scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. The assessment focuses on clinicians' observations of change in the participant's cognitive, functional, and behavioral performance since the beginning of the study.

    Time frame: Baseline and up to approximately 24 weeks

  2. Change From Baseline in The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total Score at Week 24

    The change from baseline in ADCS-ADL score at Week 24 is presented. The ADCS-ADL is an informant-based measure of the participant's functional ability in activities of daily living (ADLs). The ADCS-ADL assesses the competence of participants with AD dementia in basic and instrumental ADLs. The ADCS-ADL is a 23-item scale that includes 6 basic ADL items and 17 instrumental ADL items that provide a total score ranging from 0 to 78, with a lower score indicating greater severity.

    Time frame: Baseline and up to approximately 24 weeks

  3. Change From Baseline in the ADAS-Cog11 Total Score at Week 12

    The change from baseline in ADAS-Cog11 score at Week 12 is presented. ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of spoken language. The total possible score ranges from 0 to 70, with higher scores indicating greater cognitive impairment. Negative values indicate improvement relative to baseline, and vice versa.

    Time frame: Baseline and up to approximately 12 weeks

  4. ADCS-CGIC Overall Score at Week 12

    The overall score in ADCS-CGIC at Week 12 is presented. The ADCS-CGIC is a clinician-rated measure of change in global severity from baseline, scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. The assessment focuses on clinicians' observations of change in the participant's cognitive, functional, and behavioral performance since the beginning of the study.

    Time frame: Baseline and up to approximately 12 weeks

  5. Change From Baseline in the ADCS-ADL Total Score at Week 12

    The change from baseline in ADCS-ADL score at Week 12 is presented. The ADCS-ADL is an informant-based measure of the participant's functional ability in activities of daily living (ADLs). The ADCS-ADL assesses the competence of participants with AD dementia in basic and instrumental ADLs. The ADCS-ADL is a 23-item scale that includes 6 basic ADL items and 17 instrumental ADL items that provide a total score ranging from 0 to 78, with a lower score indicating greater severity.

    Time frame: Baseline and up to approximately 12 weeks

07

Study locations

72 sites
  • Banner Alzheimer's Institute ( Site 0110)
    Phoenix, Arizona 85006, United States
  • Irvine Clinical Research ( Site 0104)
    Irvine, California 92614, United States
  • Anderson Clinical Research ( Site 0164)
    Redlands, California 92374, United States
  • California Neuroscience Research ( Site 0118)
    Sherman Oaks, California 91403, United States
  • JEM Research Institute / Headlands Research Network ( Site 0108)
    Atlantis, Florida 33462, United States
  • Brain Matters Research-Neurology ( Site 0150)
    Delray Beach, Florida 33445, United States
  • Neuropsychiatric Research Center of Southwest Florida ( Site 0152)
    Fort Myers, Florida 33912, United States
  • Indago Research & Health Center, Inc ( Site 0128)
    Hialeah, Florida 33012, United States
  • K2 Medical Research THE VILLAGES ( Site 0166)
    Lady Lake, Florida 32159, United States
  • K2 Medical Research ( Site 0103)
    Maitland, Florida 32750, United States
  • Premier Clinical Research Institute ( Site 0114)
    Miami, Florida 33122, United States
  • Aqualane Clinical Research ( Site 0116)
    Naples, Florida 34105, United States
  • Headlands Research Orlando ( Site 0169)
    Orlando, Florida 32806, United States
  • Brain Matters Research ( Site 0151)
    Stuart, Florida 34997, United States
  • K2 Medical Research ( Site 0165)
    Tampa, Florida 33634, United States
  • Columbus Memory Center ( Site 0197)
    Columbus, Georgia 31909, United States
  • CenExel iResearch, LLC ( Site 0134)
    Savannah, Georgia 31405, United States
  • Tandem Clinical Research ( Site 0101)
    Marrero, Louisiana 70072, United States
  • Pharmasite Research, Inc. ( Site 0167)
    Baltimore, Maryland 21208, United States
  • Quest Research Institute ( Site 0173)
    Farmington Hills, Michigan 48334, United States
  • Velocity Clinical Research, Syracuse ( Site 0125)
    East Syracuse, New York 13057, United States
  • Mid Hudson Medical Research ( Site 0191)
    New Windsor, New York 12553, United States
  • Flourish Research - Charlotte ( Site 0106)
    Matthews, North Carolina 28105, United States
  • Velocity Clinical Research - Raleigh ( Site 0123)
    Raleigh, North Carolina 27607, United States
  • Summit Research Network ( Site 0111)
    Portland, Oregon 97210, United States
  • Kerwin Medical Center ( Site 0159)
    Dallas, Texas 75231, United States
  • Grayline Research Center ( Site 0105)
    Wichita Falls, Texas 76309, United States
  • Northwest Clinical Research Center ( Site 0102)
    Bellevue, Washington 98007, United States
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0207)
    Mar del Plata, Buenos Aires B7600FZN, Argentina
  • Hospital Italiano de Buenos Aires ( Site 0209)
    Buenos Aires, Buenos Aires F.D. C1199ABD, Argentina
  • Instituto Geriatrico Nuestra Señora de Las Nieves ( Site 0208)
    Buenos Aires, Buenos Aires F.D. C1427CCP, Argentina
  • Organizacion Medica de Investigacion - OMI S.A. ( Site 0204)
    Buenos Aires, C1015ABO, Argentina
  • Instituto Kremer ( Site 0202)
    Córdoba, X5004AOA, Argentina
  • Okanagan Clinical Trials ( Site 0001)
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Ottawa Memory Clinic ( Site 0004)
    Ottawa, Ontario K1Z 1G3, Canada
  • Toronto Memory Program ( Site 0006)
    Toronto, Ontario M3B 2S7, Canada
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico-UOSD Malattie Neurodegenerative ( Site 0903)
    Milan, Lombardy 20122, Italy
  • Fondazione IRCCS San Gerardo dei Tintori ( Site 0902)
    Monza, Monza E Brianza 20900, Italy
  • Centro S Giovanni Di Dio Fatebenefratelli ( Site 0904)
    Brescia, 25125, Italy
  • Ospedale San Raffaele. ( Site 0901)
    Milan, 20132, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0905)
    Roma, 00168, Italy
  • Association of Healthcare Corporation Koukankai Koukan Clinic ( Site 1510)
    Kawasaki, Kanagawa 210-0852, Japan
  • Kawasaki Saiwai Clinic ( Site 1501)
    Kawasaki, Kanagawa 212-0016, Japan
  • Hatsuta Neurology Clinic ( Site 1507)
    Hirakata, Osaka 573-1121, Japan
  • Nagomi Clinic ( Site 1506)
    Toyonaka, Osaka 560-0004, Japan
  • Takesato Hospital ( Site 1522)
    Kasukabe, Saitama 344-0036, Japan
  • Iwaki Clinic ( Site 1518)
    Anan, Tokushima 774-0014, Japan
  • Enomoto Internal Medicine Clinic(Chofu) ( Site 1503)
    Chōfu, Tokyo 182-0036, Japan
  • Nozomi Memory Clinic ( Site 1504)
    Mitaka, Tokyo 181-0013, Japan
  • Tokyo Metropolitan Institute for Geriatrics and Gerontology ( Site 1515)
    tabashi City, Tokyo 173-0015, Japan
  • Itsuki Hospital ( Site 1502)
    Tokushima, 770-0852, Japan
  • Brain Research Center Den Bosch B.V. ( Site 1002)
    's-Hertogenbosch, North Brabant 5223 LA, Netherlands
  • Brain Research Center. ( Site 1001)
    Amsterdam, North Holland 1081 GN, Netherlands
  • Brain Research Center Zwolle ( Site 1003)
    Zwolle, Overijssel 8025 AZ, Netherlands
  • Inha University Hospital ( Site 1601)
    Incheon, 22332, South Korea
  • Seoul National University Hospital ( Site 1604)
    Seoul, 03080, South Korea
  • Hanyang University Seoul Hospital ( Site 1605)
    Seoul, 04763, South Korea
  • Asan Medical Center ( Site 1603)
    Seoul, 05505, South Korea
  • Centro de Atención Especializada Oroitu ( Site 1211)
    Algorta, Bizkaia 48993, Spain
  • Hospital de la Santa Creu i Sant Pau ( Site 1204)
    Barcelona, Catalonia 8025, Spain
  • Hospital Universitario 12 de Octubre ( Site 1208)
    Madrid, Madrid, Comunidad de 28041, Spain
  • Hospital Universitari i Politecnic La Fe ( Site 1202)
    Valencia, Valencia 46026, Spain
  • Fundació ACE ( Site 1206)
    Barcelona, 08034, Spain
  • Hospital Universitari Vall D Hebron ( Site 1203)
    Barcelona, 08035, Spain
  • Hospital Universitario Virgen de la Macarena ( Site 1210)
    Seville, 41009, Spain
  • Brain Sciences Scotland Life Sciences-Aberdeen ( Site 1402)
    Aberdeen, Aberdeen City AB25 2XE, United Kingdom
  • Scottish Brain Sciences ( Site 1401)
    Edinburgh, Edinburgh, City of EH12 5PJ, United Kingdom
  • Moorgreen Hospital ( Site 1409)
    Southampton, Hampshire SO30 3JB, United Kingdom
  • Remind UK ( Site 1404)
    Bath, Somerset BA1 3NG, United Kingdom
  • Re:Cognition Health - Birmingham ( Site 1406)
    Birmingham, B16 8LT, United Kingdom
  • Windsor Research Unit ( Site 1403)
    Cambridge, CB21 5EF, United Kingdom
  • Campus for Ageing and Vitality ( Site 1408)
    Newcastle upon Tyne, NE4 5PL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jun 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Dec 6, 2024
StartActual
Dec 16, 2024
Primary completionActual
Jun 5, 2026
CompletionActual
Jun 5, 2026
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06721156
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Dec 16, 2024
Primary completion
Jun 5, 2026
Completion
Jun 5, 2026
Last update
Jul 1, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-1167

Start the discussion